Reviewer's report

Title: Phase I Dose-Escalating Study of Docetaxel in Combination with 5-Day Continuous Infusion of 5-Fluorouracil in Patients with Advanced Gastric Cancer

Version: 3 Date: 11 July 2005

Reviewer: Peter C Thuss-Patience

Reviewer's report:

General
Well written report which is now ready for publication and can be accepted.

------------------------------------------------------------------------------------------------------------------

Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached)
none, all questions answered.

------------------------------------------------------------------------------------------------------------------

Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)
page 11 last line: change "Three additional patients were enrolled...." to "Three additional patients who were enrolled...."
page 14 line 9: change "drug combination" to "drug combinations"
page 14 line 10: change "cancer was also..." to "cancer were also..."
page 15 line 4: change "...reported that docetaxel/5-FU had similar efficacy.." to "...reported that docetaxel/5-FU may have similar efficacy" (optional change, but I think it is better)
Table 2: Heading: change "After first cycle" to "After first cycle (pts)" to make clear that e.g. (1) means (1 patient had this toxicity).

------------------------------------------------------------------------------------------------------------------

Discretionary Revisions (which the author can choose to ignore)

What next?: Accept after minor essential revisions

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No

Declaration of competing interests:
I declare that I have no competing interests